User login
Credit: Andre E.X. Brown
Results of a systematic review suggest venous thromboembolism (VTE) has a high disease burden throughout the world, regardless of a country’s income.
Researchers reviewed the literature to quantify the global disease burden of VTE.
And they found that VTE associated with hospitalization was the leading cause of disability-adjusted life-years (DALYs) lost in low- and middle-income countries. It was the second most common cause of DALYs lost in high-income countries.
“Venous thromboembolism in hospitalized patients was responsible for more years lost due to ill-health than hospital-acquired pneumonia, catheter-related blood stream infections, and side effects from drugs,” said study author Gary Raskob, PhD, of the University of Oklahoma Health Sciences Center in Oklahoma City.
Dr Raskob and his colleagues reported these results in the Journal of Thrombosis & Haemostasis.
The team reviewed 8702 studies on VTE and found that studies from western Europe, North America, Australia, and southern Latin America (Argentina) yielded consistent results.
The annual incidence of VTE ranged from 0.75 to 2.69 per 1000 individuals in the population. The incidence increased to between 2 and 7 VTEs per 1000 people among those 70 years of age or older.
Only two studies were designed to evaluate the prevalence of VTE, and both were conducted using US data. In one study, researchers investigated the prevalence of VTE from 2002 to 2006 using a health insurance claims database of 12.7 million individuals.
VTE occurred in 3.2 enrollees per 1000 in 2002 and 4.2 per 1000 in 2006. In 2006, the prevalence of VTE was 13.8 per 1000 in enrollees age 65 and older and 2.3 per 1000 in those younger than 65 years of age.
The other study designed to assess VTE prevalence in the US showed that prevalence was highest in African American males, followed by Caucasian males, Caucasian females, and African American females. Hispanic individuals of both sexes had the lowest prevalence rates.
Two studies were designed to evaluate VTE disease burden in terms of DALYs. The strongest of these included data from a literature review and epidemiologic studies commissioned by the WHO.
The study showed that VTE occurred in 3.3 of 100 hospitalizations in high-income countries and 3.0 of 100 hospitalizations in low-income and middle-income countries. The estimated annual cases of VTE were 3.9 million and 6.0 million, respectively.
VTE was the leading cause of hospital-related DALYs lost overall. It was responsible for a third (7681) of the 22,644 DALYs.
The researchers concluded that VTE causes a major burden of disease across low-income, middle-income, and high-income countries. However, more detailed data on the global burden of VTE is needed. 
Credit: Andre E.X. Brown
Results of a systematic review suggest venous thromboembolism (VTE) has a high disease burden throughout the world, regardless of a country’s income.
Researchers reviewed the literature to quantify the global disease burden of VTE.
And they found that VTE associated with hospitalization was the leading cause of disability-adjusted life-years (DALYs) lost in low- and middle-income countries. It was the second most common cause of DALYs lost in high-income countries.
“Venous thromboembolism in hospitalized patients was responsible for more years lost due to ill-health than hospital-acquired pneumonia, catheter-related blood stream infections, and side effects from drugs,” said study author Gary Raskob, PhD, of the University of Oklahoma Health Sciences Center in Oklahoma City.
Dr Raskob and his colleagues reported these results in the Journal of Thrombosis & Haemostasis.
The team reviewed 8702 studies on VTE and found that studies from western Europe, North America, Australia, and southern Latin America (Argentina) yielded consistent results.
The annual incidence of VTE ranged from 0.75 to 2.69 per 1000 individuals in the population. The incidence increased to between 2 and 7 VTEs per 1000 people among those 70 years of age or older.
Only two studies were designed to evaluate the prevalence of VTE, and both were conducted using US data. In one study, researchers investigated the prevalence of VTE from 2002 to 2006 using a health insurance claims database of 12.7 million individuals.
VTE occurred in 3.2 enrollees per 1000 in 2002 and 4.2 per 1000 in 2006. In 2006, the prevalence of VTE was 13.8 per 1000 in enrollees age 65 and older and 2.3 per 1000 in those younger than 65 years of age.
The other study designed to assess VTE prevalence in the US showed that prevalence was highest in African American males, followed by Caucasian males, Caucasian females, and African American females. Hispanic individuals of both sexes had the lowest prevalence rates.
Two studies were designed to evaluate VTE disease burden in terms of DALYs. The strongest of these included data from a literature review and epidemiologic studies commissioned by the WHO.
The study showed that VTE occurred in 3.3 of 100 hospitalizations in high-income countries and 3.0 of 100 hospitalizations in low-income and middle-income countries. The estimated annual cases of VTE were 3.9 million and 6.0 million, respectively.
VTE was the leading cause of hospital-related DALYs lost overall. It was responsible for a third (7681) of the 22,644 DALYs.
The researchers concluded that VTE causes a major burden of disease across low-income, middle-income, and high-income countries. However, more detailed data on the global burden of VTE is needed.
Credit: Andre E.X. Brown
Results of a systematic review suggest venous thromboembolism (VTE) has a high disease burden throughout the world, regardless of a country’s income.
Researchers reviewed the literature to quantify the global disease burden of VTE.
And they found that VTE associated with hospitalization was the leading cause of disability-adjusted life-years (DALYs) lost in low- and middle-income countries. It was the second most common cause of DALYs lost in high-income countries.
“Venous thromboembolism in hospitalized patients was responsible for more years lost due to ill-health than hospital-acquired pneumonia, catheter-related blood stream infections, and side effects from drugs,” said study author Gary Raskob, PhD, of the University of Oklahoma Health Sciences Center in Oklahoma City.
Dr Raskob and his colleagues reported these results in the Journal of Thrombosis & Haemostasis.
The team reviewed 8702 studies on VTE and found that studies from western Europe, North America, Australia, and southern Latin America (Argentina) yielded consistent results.
The annual incidence of VTE ranged from 0.75 to 2.69 per 1000 individuals in the population. The incidence increased to between 2 and 7 VTEs per 1000 people among those 70 years of age or older.
Only two studies were designed to evaluate the prevalence of VTE, and both were conducted using US data. In one study, researchers investigated the prevalence of VTE from 2002 to 2006 using a health insurance claims database of 12.7 million individuals.
VTE occurred in 3.2 enrollees per 1000 in 2002 and 4.2 per 1000 in 2006. In 2006, the prevalence of VTE was 13.8 per 1000 in enrollees age 65 and older and 2.3 per 1000 in those younger than 65 years of age.
The other study designed to assess VTE prevalence in the US showed that prevalence was highest in African American males, followed by Caucasian males, Caucasian females, and African American females. Hispanic individuals of both sexes had the lowest prevalence rates.
Two studies were designed to evaluate VTE disease burden in terms of DALYs. The strongest of these included data from a literature review and epidemiologic studies commissioned by the WHO.
The study showed that VTE occurred in 3.3 of 100 hospitalizations in high-income countries and 3.0 of 100 hospitalizations in low-income and middle-income countries. The estimated annual cases of VTE were 3.9 million and 6.0 million, respectively.
VTE was the leading cause of hospital-related DALYs lost overall. It was responsible for a third (7681) of the 22,644 DALYs.
The researchers concluded that VTE causes a major burden of disease across low-income, middle-income, and high-income countries. However, more detailed data on the global burden of VTE is needed.